Chapter-1 EFFECT OF A FEW ANTIDEPRESSANTS ON SEXUAL BEHAVIOR OF DROSOPHILA MELANOGASTER

Size: px
Start display at page:

Download "Chapter-1 EFFECT OF A FEW ANTIDEPRESSANTS ON SEXUAL BEHAVIOR OF DROSOPHILA MELANOGASTER"

Transcription

1 Chapter-1 EFFECT OF A FEW ANTIDEPRESSANTS ON SEXUAL BEHAVIOR OF DROSOPHILA MELANOGASTER

2 Introduction All animals exhibit innate behaviors that are specified during their development. Sexual behavior is one such innate behavior performed by the male towards the female. Courtship and mating are part of this sexual behavior and these two activities are important events in the life of the sexually reproducing organisms. A few workers have used sexual behavior as one of the parameters in understanding the evolutionary relationship among closely related organisms. One of the advantages of using behavior as a means for studying the evolution of a group of closely related organism is that the investigators performance must study living organisms, and by inclination often checks his laboratory findings against field studies, thus acquiring a healthy respect for the all pervading power of selection (Tinbergen 1963). The sexual behavior is the action of structure responding to stimuli, either internal or external, that have been received, perceived, and processed by the organism. Drosophila although is a tiny insect, displays an elaborate courtship which could be easily observed and recorded (Spieth 1966). The sexual behavior of Drosophila is a sequential stereotyped stepwise display which exhibits an interesting series of courtship elements consisting of various behavioral displays followed by an interchange of different sensory stimuli (visual, acoustic, olfactory and tactile). Courtship is the behavior that accounts for most of their social life,it is rich in content, complex in structure and robust in execution. As an essential piece in the fly s evolutionary repertoire, it is not surprising that reproductive behavior should be reinforced and buffered against deleterious events, whether developmental or experimental, that might subvert it. Sexual behavior is likely to be the most contextdependent of all phenotypes and thus subject to many influences that are external to the individual (Greenspan 2000). 1

3 Although primarily behavior has been used in understanding the evolutionary pathway of different groups of organisms, it has also been used for investigation of many other aspects of biology. The developmental patterns, mechanisms that underlie in gene expression, complex physiological mechanisms of many metabolic activities have been understood using different behavioral activities. Unlike morphology, behavior has the disadvantage that it is a transient activity performed by the creatures being studied and therefore cannot be preserved for later review. It is, indeed, imperative that the behavioral elements of the organisms be perceived as they occur and recorded by the observer for future reference. Behavior involves a series of complex activities of the organism that are serially expressed. A behavioral act is a reflection of co-ordinated function of many morphological and/or physiological traits. Realizing this, a few workers have used the sexual behavior as a parameter for evaluating the effects of a few antiepileptic and antidepressant drugs, carcinogens, mutagens and other toxic substances. For example, Mos et al (1999) studied the effect of a few selective serotonin reuptake inhibitors (SSRIs) on the sexual behavior of male rats. Nazari (2004) studied the effect of two antidepressant drugs, fluoxetine and amitryptyline both belonging to SSRI on sexual behavior of Drosophila melanogaster. In the light of this the present study has also been carried out on the effect of all four classes of antidepressant drugs on the sexual behavior of Drosophila. 2

4 Review of literature A review of literature reveals that there are several investigation on the effect of drugs, antibiotics, pesticides and other toxic chemicals on Drosophila. Nazir et al (2001) suggests that certain larval tissues of Drosophila, a non target organism are vulnerable to chlorpyrifos. Further, the adverse effect of the toxicant reflected on various stages of development of the fly including reproductive performance. The genotoxicity of acrolein in D. melanogaster was investigated using 2 different SMART assays, the eye spot and wing spot tests, and 2 germinal tests, the sex-linked recessive lethal (SLRLT) and sex chromosome loss (SCLT) tests (Sierra et al 1994). Three well known chemical oxidative stress inducers: hydrogen peroxide (H 2 O 2 ), cadmium chloride (CdCl 2 ) and copper sulfate (CuSO 4 ) showed that the modified Alkaline Comet Assay can be used to detect oxidative stress-induced DNA damage in D. melanogaster and thus may be applicable for in vivo genotoxic assessments of environmental chemicals (Shukla et al 2011). David et al (1997) tested for mutagenic effects of cryopreservation in D. melanogaster embryos with an X- linked, recessive lethal assay. The action of several metabolism modifiers, namely phenobarbital, an inducer of xenobiotic metabolism, phenylimidazole and iproniazid, inhibitors of oxidative activities of cytochrome P450, and diethyl maleate, a glutathione-depleting agent, have been assayed using the sex-linked recessive lethal (SLRL) test on Drosophila (Barros et al 2011). Depression is a common psychiatric disorder and leading cause of disability worldwide. It is associated with increased mortality, especially from suicide. Heritability is estimated around 40% suggesting that genotyping is a promising field for research in to the development of depression (Harris and Barraclough 1998; 3

5 Schneider et al 2001). According to the dopamine theory of affective disorder, a deficiency in neurotransmission may play a major role in the disorder; specific polymorphism in genes that affect neurotransmission could increase susceptibility (Opmeer et al 2009) Antidepressants are drugs of long term use administered to number of patients. In the evaluation of the benefit /risk ratio it should be considered that among the various adverse reactions that these drugs might cause the occurrence of effect on behavior cannot be excluded. A growing body of evidence has suggested that antidepressant effects can be extended from depressive symptomatology also to personality characteristics that do not fall within the pathological realm. Kramer (1993) has found that subjects with antidepressants showed changes both in symptomatology and also in psychological traits. Medication in most cases may produce health effects of variable degree, which in some cases may be a serious human health hazard. This potential damage is of particular concern with respect to compounds used for long periods. The antidepressants studied are medicaments that may be continuously consumed for 6 months or longer, with a possible repetition of the treatment (Frommer and Kulig 1987). Also, there have been reports showing collateral health effects, mainly on the cardiovascular system (Fasoli and Glauser 1981; Burrows and Vohra 1986). Other types of alterations have been described as well: for eg, myoclonous, sexual dysfunction and hyponatremia (Black and Kilzich 1994; Colgate 1993). Most antidepressant drugs have adverse effects on sexual function, but accurate identification of the incidence of treatment-emergent dysfunction has proved troublesome. Growing awareness of the adverse effects of many antidepressants on 4

6 sexual dysfunction has led to attempts to resolve dysfunction through adjuvant or substitution treatment approaches. Yet many of these attempts are unsuccessful in solving these problems. Therefore there is a need for further studies on the effects of antidepressants on sexual function. In the past, most of the studies on the genetic effects of anticancer drugs have been concentrated on cytogenetic damage (Clements et al 1990). However, it is obviously important to learn more about the different types of mutagenic lesions induced by anticancer drugs. Also, Tiburi et al (2002) reported that vincristine (VCR), vinblastine induced genetic toxicity causing increments in the incidence of mutational events, as well as in somatic recombination in D. melanogaster. The effect of antipsychotics fluphenazine showed sex linked recessive lethal mutations in D. melanogaster (Schaik and Graf 1993) and also the result obtained on work carried by Gocke (1996) revealed positive result of trifluperazine on sex linked recessive lethal mutation on Drosophila. Chlorpromazine also affected on somatic mutation in Drosophila. Although antidepressants of different class were assessed clomipramine, desipramine and imipramine showed somatic mutation and recombination on Drosophila (Balbi et al 1980) where as lofepramine, maprotiline and mianserin are assessed by (Schaik and Graf 1993). Schaik and Graf (1991) also showed effect of protryptyline on somatic mutation and recombination in Drosophila. Tricyclic antidepressants also ricochet off other sites in the central as well as peripheral nervous system. Depending on dosage, TCAs may disrupt brain regions that control heart rate, appetite, muscle tension and sexual function to the point where a person is severely debilitated. The anticholinergic properties of TCAs are responsible for their many undesirable side effects, such as dry mouth and eyes, 5

7 constipation etc. TCAs can also cause loss of sex drive. The most dangerous side effects of it are hypertension, tachycardia or suffer from seizure (Mitchell 2004). Although antidepressants are given to reduce depression, some of them are believed to have side effects, they also carry a risk for increased hostility, agitation and anxiety, and antidepressants may raise a heart patient's risk of dying in 3 years (Harrar and Gould, 2006). Antidepressants deplete neurotransmitter level specifically serotonin, norepinephrine and dopamine are prevalent in the areas of brain like the limbic system and upper brain stem which controls mood and emotion. The depletion of neurotransmitters are believed to influence sexual dysfunction (Hinz 2011) with some common side effects like nausea, agitation, constipation, abdominal pain, tremor, sweating, decreased libido, sexual dysfunction is most common. It is reported that some of the antidepressant drugs cause sexual dysfunction. Although a few studies on the effect of antidepressants on sexual behavior are made they have certain experimental flaw. Only few studies followed a recognized measure (Hamilton rating scale) for sexual dysfunction, the others relying on patients reporting adverse events (Baldwin 2001). In spite of this the antidepressants are being prescribed because in disease treatment, the effect of the administered drug on sexual activity is not taken seriously. Whether all the antidepressants have such effects on sexual activity is also not known. If the antidepressants affect the sexual behavior, and sexual behavior being a fitness character, continuous administration of it could affect the reproductive potentiality. Such long term effects of antidepressants have also not been analyzed. This prompted the author to take up the present studies on the effect of these antidepressant drugs on the sexual behavior of Drosophila. The effect has been studied in flies with each of the four different classes of antidepressant and their progenies. 6

8 Materials and methods Materials: 1. Model organism: Standard Oregon K (OK) strain Drosophila melanogater obtained from Drosophila stock centre, Department of Zoology, University of Mysore, Mysore Karnataka, India was used. 2. Antidepressant drugs: For treatment of depression, four different classes of antidepressants are commercially available. Therefore in the present study the effect of one antidepressant drug from each class was studied. The drugs selected for the study were as follows, Sertraline: Sertraline is a drug belonging to selective serotonin reuptake inhibitors (SSRI) which inhibit the inactivation of serotonin (5-hydroxytryptamine or 5-HT) by blocking its absorption in the central nervous system. The hydrochloride of sertraline is a white crystalline powder; slightly soluble in water and alcohols (ethanol, isopropyl alcohol). Its melting point is C; and molecular weight is The chemical designation is (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-n-methyl-1-naphthalenamine hydrochloride. Sertraline is absorbed readily through the gastrointestinal tract. Its absolute bioavailability has not been determined in humans. Maximum plasma concentrations of following doses of 50 and 200 mg are µg/l (ng/ml). Serum levels at steady state are ng/ml of sertraline and its desmethyl metabolites. Plasma protein binding is extensive (approx 98%) to both albumin and alpha1-acid glycoprotein. Distribution following oral administration of sertraline is biphasic with a prolonged absorption phase. The elimination phase begins hr following the administration. The volume of distribution has not been determined in humans but is more than 20 L/kg in rats and dogs. Both sertraline 7

9 and its metabolites exhibit extensive distribution into tissues outside the blood. The elimination half-life (beta) of sertraline in humans is hr. The clinically active desmethyl metabolite is eliminated more slowly than the parent drug with a half-life of approx 66 hr. Unchanged sertraline is not detected in the urine. Bioavailability and absorption rate are increased if sertraline is taken with food. In the present study Sertra-100, a drug manufactured by M/S Unichem Laboratories Ltd, India was used. Duloxetine: Duloxetine belonging to Serotonin Noradrenergic Reuptake Inhibitors (SNRIs) with a Molecular weight of and Melting Point of C, freely soluble in water, methanol, ethanol, chloroform and methylene chloride and sparingly soluble in diethyl ether. The absorption of duloxetine is rapid and at least 90% is absorbed. Elimination of duloxetine and its metabolites is predominantly through the urine; greater than 90% of a dose is recovered in urine and about 5% of a dose is recovered in the feces over 96 hours. In the present study Duxela-60, a derivative of duloxetine hydrochloride manufactured from M/S Sun Pharmaceuticals Private Limited was used. Doxepin : Doxepin hydrochloride belongs to Tricyclic antidepressants. It has histamine receptor blocking actions, the exact mechanism by which doxepin exerts its antipyritic effect is unknown. Plasma doxepin concentrations level is 47 ng/ml from percutaneous absorption. Plasma levels from topical application of doxepin can result in CNS and other systemic side effects. Doxepin hydrochloride has an empirical formula of C19H21NO HCl and a molecular weight of 316 and its melting point ºC. Desmethyldoxepin has a half-life that ranges from 28 to 52 hours and is not affected by multiple dosing. Renal disease, genetic factors, age, and other medications affect the metabolism and subsequent elimination of doxepin. Spectra-25 8

10 a derivative of doxepin manufactured by M/S Rexcin Pharmaceuticals Private Limited was used here. Nortryptyline: Nortriptyline belongs to the category Monoamine oxidase inhibitors It has poor long-term efficacy with a high relapse rate in individuals being for depression, possibly due to a toxic metabolite 10-hydroxynortriptyline, being produced. Thus it is significantly inferior to other and older antidepressants. Nortriptyline is metabolised in the liver by hepatic enzyme CYP2D6. Blood levels of nortriptyline should be obtained during long term treatment to avoid toxicity and optimise response. Nortryptyline is insoluble in water but soluble in organic solvents, such as pentane. At room temperature it is a colorless crystalline solid. It has a molecular weight and Melting point of 189 to193ºc. Sensival, a derivative of nortryptyline manufactured by M/S Wallace Pharmaceutical Private Limited was used in present study. Toxicity measurement: The toxicity of the above four drugs were measured by feeding appropriate doses. Then the LC 50 was estimated on the basis of the concentration tested in the toxicity analysis. Based on the probit analysis, sublethal concentrations of each drug was chosen for analysis of the effect of these drugs on the sexual behavior and the reproductive fitness of Drosophila melanogaster. A. Preparation of standard medium: The flies of Oregon-K strain of Drosophila melanogaster were acclimatized to laboratory condition for five to six generation at a temperature 22 ± 2ºC in a standard soji agar medium prepared as described by (Hegde et al 2001). To prepare one litre of the standard medium, 120 gms of jaggery was dissolved in 1000 ml of boiling water. 100gm of soji powder was added to this 9

11 solution while boiling. Gentle stirring is needed to avoid the formation of lumps. 10 gms of agar agar was added to this mixture and then 7.5ml of propionic acid was added. The medium was cooked well, distributed to either 100 quarter pint (250 ml) milk bottles or 1000 glass vials (3"X1" dia) and allowed to cool. Next day, 5-10 yeast granules were added and flies were transferred and maintained in the standard laboratory condition. Table 1. Showing log-dose/probit of antidepressants for estimating their LC50. Antidepressants LC50 Sublethal concentration Regression equation Sertraline 1.25mg/100ml 0.2%; 0.4%; 0.6% Y= Duloxetine 15mg/100ml 3%; 6%; 12% Y= Doxepin 1mg/100ml 0.125%; 0.25%; 0.5% Y= Nortryptyline 2mg/100ml 0.25%; 0.5%; 1.0% Y= B. Preparation of media: The Drosophila food medium was prepared as mentioned above. When once all ingredients were added and the medium is cooked sufficiently, it was removed from the flame and then the appropriate concentration of the drug was added to it (The concentration of each drug used in the present study is shown in table 1). The media was stirred well and then distributed to glass vials and then allowed to cool. C. Study of sexual behavior of antidepressant flies: Freshly emerged virgin females and naïve males were sorted by sex and separately maintained in the glass vials with a normal media for three days. Three day old flies were starved to 8hrs and fed in media supplemented by respective concentration of drugs. These flies were then allowed to feed this food supplemented with the drug for two days. Thus 5days old drug fed male and drug fed female were aspirated out and placed in an mating chamber and allowed to undergo mating where as flies fed in normal media 10

12 were assessed as control or un. The sexual behavior such as courtship latency, mating latency and copulation duration was studied following the procedure described by Hegde and Krishna (1997). While making observation of sexual behavior following combination of pairs were made. Group-I Male un X Female un (Control) Group-II Female X Male un (Only female ) Group-III Male X Female un (Only male ) Group-IV Female X Male (Both ). After completion of mating each pair was transferred to vials containing normal food medium. The pairs were allowed to lay eggs, and produce the progeny. The virgin females and naïve males emerged from each pair were separated, aged for five days and their behavior was also studied. A total of 20 pairs were observed for each drug in all the above four combinations. The pairs after mating were kept separately and allowed to produce the progeny. The sexual behavior of flies obtained in the progeny was also studied. The data obtained were pooled together, means and standard errors were calculated. Student t-test was applied to know the effect of the drug on the above behavioral traits. 11

13 Results Table 2. Showing mean duration in minutes, standard error and student t-test of courtship latency of sertraline and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Parent F1 t-values Treatment Means ±S.E Means ±S.E t-values Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * 3.18* 3.91* 3.53 ± * 3.57* 4.21* Female 0.2% 5.80 ± 0.74 X ± 0.42 X 2.83* 3.03* 0.4% 4.01 ± 0.07 X X ± 0.52 X X 3.23* 0.6% 7.50 ± 0.91 X X X 2.20 ± 0.27 X X X Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * 4.23* 3.16* 3.43 ± * 3.72* Male 0.2% 4.43 ± 0.10 X * 4.50 ± 0.24 X % 4.41 ± 0.21 X X ± 0.42 X X % 2.75 ± 1.03 X X X 2.13 ±0.1 X X X Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * 3.18* 3.91* 3.50 ± * 2.21* 2.41* Both sex 0.2% ± 0.31 X ± 0.65 X 1.21* 2.26* 0.4% 7.40 ± 0.98 X X ± 1.74 X X 2.20* 0.6% 4.70 ± 0.64 X X X 3.40 ± 0.57 X X X *indicates P-value significant at 0.05 level 12

14 Table 3. Showing mean duration in minutes, standard error and student t-test of courtship latency of duloxetine and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Female Male Both sex Treatment Parent Means ± S.E t-values F1 Means ± S.E t-values Parent 3% 6% 12% F1 3% 6% 12% Control ± * 4.02* 4.50* 13.53± * 4.10* 2.67* 3% ± 0.74 X 2.91* 3.38* 17.65± 1.87 X * 6% ± 0.07 X X 3.54* ± 0.56 X X 5.02* 12% ± 0.91 X X X ± 1.05 X X X Parent 3% 6% 12% F1 3% 6% 12% Control ± * 4.90* 4.37* 13.43± * 2.93* 3.72* 3% ± 0.10 X 2.40* ± 1.87 X * 6% ± 0.21 X X ± 0.56 X X 2.83* 12% ± 1.03 X X X ± 0.86 X X X Parent 3% 6% 12% F1 3% 6% 12% Control 12.45± * 2.48* 2.02* ± * 9.72* 2.89* 3% ± 2.18 X ± 1.65 X 4.21* 3.38* 6% ± 0.98 X X ± 0.74 X X 5.66* 12% ± 0.92 X X X 4.70 ± 0.57 X X X *indicates P-value significant at 0.05 level 13

15 Table 4. Showing mean duration in minutes, standard error and student t-test of courtship latency of doxepin and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Female Male Both sex Treatment Parent F1 t-values Means ±S.E Means ± S.E t-values Parent 0.125% 0.25% 0.5% F % 0.25% 0.5% Control 5.13 ± * 9.13* 7.90* 4.82 ± * 6.57* 6.66* 0.125% 7.22 ± 0.28 X ± 0.80 X 11.69* 10.04* 0.25% 3.17 ± 0.66 X X 3.06* 1.83 ± 0.62 X X % 1.70 ± 0.43 X X X 4.05 ± 0.83 X X X Parent 0.125% 0.25% 0.5% F % 0.25% 0.5% Control 2.61 ± * ± * 8.53* 4.04* 0.125% 7.10 ± 1.09 X 4.42* ± 0.66 X 6.60* 9.06* 0.25% 4.14 ± 0.78 X X 3.82* 2.64± 0.32 X X 9.95* 0.5% 1.83 ± 0.45 X X X 2.05 ±0.04 X X X Parent 0.125% 0.25% 0.5% F % 0.25% 0.5% Control 3.38± * 2.14* ± % ± 0.38 X 3.70* 2.84* 2.20 ± 0.10 X 3.61* % 4.76 ± 1.00 X X ± 0.79 X X 6.32* 0.5% 5.82 ± 0.85 X X X 2.70 ± 0.85 X X X *indicates P-value significant at 0.05 level 14

16 Table 5. Showing mean duration in minutes, standard error and student t-test of courtship latency of nortryptyline and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Female Male Both sex Treatment Parent Means + S.E t-values F1 Means + S.E t-values Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control 2.50 ± * 4.48* 6.95* 2.40 ± * % 1.85 ± 0.17 X 3.63* 2.84* 2.00± 0.66 X % 2.05 ± 0.29 X X 2.74* 2.58 ± 1.26 X X % 7.78 ± 0.74 X X X 2.90 ± 0.33 X X X Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control 2.00 ± * 2.40* 2.05* 2.60 ± * 0.25% 7.63 ± 0.62 X * 1.88 ± 0.42 X 6.38* 2.08* 0.5% 5.18 ± 1.02 X X 2.30* 2.85 ± 0.54 X X 4.74* 1.0% 3.52 ± 0.88 X X X 1.90 ± 0.46 X X X Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control 2.36± * ± * 7.70* 3.16* 0.25% 3.50 ± 0.79 X * 2.75 ± 0.05 X 4.70* 7.14* 0.5% 3.60 ± 0.13 X X 2.84* 5.35± 0.21 X X 3.19* 1.0% 5.25 ± 0.34 X X X 2.45 ± 0.70 X X X *indicates P-value significant at 0.05 level 15

17 Table 6. Showing mean duration in minutes, standard error and student t-test of mating latency of sertraline and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Female Male Both sex Treatment Parent Means ± S.E *indicates P-value *indicates P-value significant at 0.05 level t-values F1 Means ± S.E t-values Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * 3.39* ± * 4.27* 3.91* 0.2% 7.93 ± 0.95 X ± 0.72 X % 6.72 ± 1.35 X X ± 0.73 X X % ± 2.98 X X X 16.50±3.39 X X X Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * 4.97* 5.01* 9.62 ± * 0.2% 6.37 ± 0.16 X 3.90* ± 1.27 X % ± 3.12 X X 3.87* ±1.68 X X % 6.56 ± 0.90 X X X 6.60 ± 0.47 X X X Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * * 10.7 ± * 4.23* 3.71* 0.2% ± 3.14 X * 5.50 ± 0.71 X % ± 0.79 X X ±2.28 X X % ± 2.48 X X X 5.20 ± 0.56 X X X 16

18 Table 7. Showing mean duration in minutes, standard error and student t-test of mating latency of duloxetine and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Treatment Parent F1 t-values Means + S.E Means + S.E t-values Parent 3% 6% 12% F1 3% 6% 12% Control 16.6 ± * 2.60* ± * 4.27* 3.91* Female 3% ± 0.95 X ± 0.84 X % ± 0.35 X X ± 0.73 X X % ± 1.23 X X X ± 0.39 X X X Parent 3% 6% 12% F1 3% 6% 12% Control ± * 3.29* 4.02* 9.62± * 2.81* 3.19* Male 3% ± 0.85 X 3.90* ± 0.27 X % ± 0.98 X X ± 0.68 X X % ± 0.76 X X X ± 0.88 X X X Parent 3% 6% 12% F1 3% 6% 12% Both sex Control 16.80± * 4.50* 4.24* ± * 4.23* 3.71* 3% ± 0.54 X 3.12* 3.88* ± 0.35 X % 14.10± 014 X X 4.96* 17.50± 0.52 X X 2.31* 12% ± 0.82 X X X ± 1.15 X X X *indicates P-value significant at 0.05 level 17

19 Table 8. Showing mean duration in minutes, standard error and student t-test of mating latency of doxepin and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Treatment Parent Means + S.E t-values F1 Means + S.E t-values Female Male Both sex Parent 0.125% 0.25% 0.5% F % 0.25% 0.5% Control ± * ± % 9.22 ± 1.02 X ± 1.61 X % ± 1.66 X X ± 0.83 X X % 2.75 ± 0.53 X X X 1.41 ± 0.67 X X X Parent 0.125% 0.25% 0.5% F % 0.25% 0.5% Control 4.33 ± ± * 2.93* % 9.16 ± 0.59 X ± 0.98 X * 0.25% ± 0.53 X X ± 1.36 X X 2.22* 0.5% 6.16 ± 0.93 X X X 4.00 ±0.30 X X X Parent 0.125% 0.25% 0.5% F % 0.25% 0.5% Control 7.83± * 2.05* 3.79* 2.27 ± * % ± 1.14 X 6.54* 2.62* 3.50 ± 0.97 X 5.79* % 8.50 ± 2.09 X X ± 0.65 X X % ± 0.60 X X X 4.60 ± 1.06 X X X *indicates P-value significant at 0.05 level 18

20 Table 9. Showing mean duration in minutes, standard error and student t-test of mating latency of nortryptyline and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Female Male Both sex Treatment Parent F1 t-values Means + S.E Means + S.E t-values Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control 3.73 ± * 5.05* 3.47* 5.65 ± * * 0.25% ± 1.84 X 5.37* 4.42* 4.05± 1.20 X 5.68* 5.27* 0.5% 5.25 ± 0.23 X X 4.07* 6.35 ± 1.52 X X 3.09* 1.0% 4.05 ± 0.48 X X X 4.95 ± 1.47 X X X Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control 4.35 ± * 1.84* 5.31± * 6.06* % ± 0.90 X 4.10* 3.79* 4.00 ± 0.72 X * 0.5% 9.00 ± 0.58 X X ± 0.83 X X % ± 1.19 X X X 5.31 ± 0.76 X X X Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control 7.84± * * 5.15 ± * % 14.60±0.88 X 3.47* ± 1.20 X 5.05* 2.21* 0.5% 8.92 ± 0.67 X X 2.21* 10.09± 0.44 X X 5.78* 1.0% ± 1.21 X X X 4.90 ± 1.35 X X X *indicates P-value significant at 0.05 level 19

21 Table 10. Showing mean duration in minutes, standard error and student t-test of copulation duration of sertraline and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Treatment Parent Mean ± S.E t-values F1 Mean ± S.E t-values Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * 3.15* 3.78* ± * 4.76* 3.98* Female 0.2% ± 1.56 X 2.67* 3.56* ± 1.21 X 2.61* 3.19* 0.4% ± 1.75 X X 3.84* ± 0.78 X X % ± 1.22 X X X ± 1.20 X X X Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * 2.92* 3.10* ± * 4.30* 3.89* Male 0.2% ± 0.14 X * ± 1.31 X % ± 0.90 X X 2.86* ± 1.25 X X % ± 0.69 X X X ± 0.68 X X X Parent 0.2% 0.4% 0.6% F1 0.2% 0.4% 0.6% Control ± * 4.30* 3.61* ± * 4.20* 3.19* Both sex 0.2% ± 0.52 X ± 1.10 X % 15.0 ± 1.15 X X ± 1.11 X X % ± 0.87 X X X 17.0 ± 0.77 X X X *indicates P-value significant at 0.05 level 20

22 Table 11. Showing mean duration in minutes, standard error and student t-test of copulation duration of duloxetine and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Treatment Parent Means + S.E t-values F1 Means + S.E t-values Parent 3% 6% 12% F1 3% 6% 12% Control ± * 3.18* 3.78* ± * 4.76* 3.98* Female 3% ± 0.60 X ± 0.36 X 2.61* 3.19* 6% ± 0.60 X X ± 1.68 X X 2.09* 12% ± 1.22 X X X ± 1.02 X X X Male Both sex Parent 3% 6% 12% F1 3% 6% 12% Control ± * 2.67* ± * 4.30* 3.89* 3% ± 1.18 X 3.70* ± 0.24 X % ± 1.25 X X 4.79* ± 0.25 X X % ± 0.97 X X X ± 1.04 X X X Parent 3% 6% 12% F1 3% 6% 12% Control ± * 2.09* 2.70* ± * 4.20* 3.19* 3% ± 0.30 X ± 0.22 X % ± 1.15 X X 2.28* ± 1.39 X X % ± 1.01 X X X ± 0.88 X X X *indicates P-value significant at 0.05 level 21

23 Table 12. Showing mean duration in minutes, standard error and student t-test of copulation duration of doxepin and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Treatment Parent F1 t-values Means + S.E Means + S.E t-values Parent 0.5% 0.25% 0.125% F1 0.5% 0.25% 0.125% Control ± * * ± * Female 0.5% ± 2.91 X 4.21* 4.63* ± 1.46 X 6.76* 7.01* 0.25% 24.7 ± 1.67 X X 2.57* ± 1.44 X X 6.76* 0.125% ± 2.75 X X X ± 0.10 X X X Parent 0.5% 0.25% 0.125% F1 0.5% 0.25% 0.125% Control ± * 9.33* 3.28* ± * 5.44* 3.34* Male 0.5% ± 1.07 X 5.15* ± 3.70 X 3.92* 3.63* 0.25% ± 2.32 X X 2.86* ± 1.65 X X 3.54* 0.125% ± 1.33 X X X ±1.49 X X X Parent 0.5% 0.25% 0.125% F1 0.5% 0.25% 0.125% Control ± * ± * Both sex 0.5% ± 1.25 X * ± 3.92 X 5.79* 5.47* 0.25% ± 2.24 X X 6.92* ± 3.46 X X % ± 1.89 X X X ± 2.65 X X X *indicates P-value significant at 0.05 level 22

24 Table 13. Showing mean duration in minutes, standard error and student t-test of copulation duration of nortryptyline and un groups of D.melanogaster flies and their progeny (The values after the decimal point is seconds). Crosses Female Male Both sex Parent F1 t-values Treatment Means + S.E Means + S.E t-values Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control ± ± * % ± 0.84 X 5.86* ± 0.72 X * 0.5% ± 3.85 X X 5.98* ± 1.27 X X 6.40* 1.0% ± 0.93 X X X ± 0.83 X X X Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control ± * 19.30± * * 0.25% ± 0.92 X * ± 0.97 X 5.60* 6.18* 0.5% ± 1.04 X X 3.60* ± 1.45 X X 3.60* 1.0% ± 1.03 X X X ± 0.76 X X X Parent 0.25% 0.5% 1.0% F1 0.25% 0.5% 1.0% Control 20.31± * ± * 2.86* 6.02* 0.25% ± 1.21 X 2.25* 2.18* ± 1.29 X 2.28* % ± 2.99 X X 2.67* ± 0.87 X X 2.38* 1.0% ± 1.70 X X X ± 1.10 X X X *indicates P-value significant at 0.05 level 23

25 Adult Progeny Figure 1: Showing courtship latency of D.melanogaster flies with sertraline. Adult Progeny Figure 2: Showing courtship latency of D.melanogaster flies with duloxetine. 24

26 Adult Progeny Figure 3: Showing courtship latency of D.melanogaster flies with doxepin. Adult Progeny Figure 4: Showing courtship latency of D.melanogaster flies with nortryptyline. 25

27 Adult Progeny Figure 5: Showing mating latency of D.melanogaster flies with sertraline. Adult Progeny Figure 6: Showing mating latency of D.melanogaster flies with duloxetine. 26

28 Adult Progeny Figure 7: Showing mating latency of D.melanogaster flies with doxepin. Adult Progeny Figure 8: Showing mating latency of D.melanogaster flies with nortryptyline. 27

29 Adult Progeny Figure 9: Showing copulation duration of D.melanogaster flies with sertraline. Adult Progeny Figure 10: Showing copulation duration of D.melanogaster flies with duloxetine. 28

30 Adult Progeny Figure 11: Showing copulation duration of D.melanogaster flies with doxepin. Adult Progeny Figure 12: Showing copulation duration of D.melanogaster flies with nortryptyline. 29

31 Results The courtship latency of D.melanogaster flies with different concentrations of sertraline is provided in table 2 and figures 1. The effect of sertraline on the progeny of these flies is also given here. The scrutiny of the table shows that the courtship latency (13.82 ± 0.31) of flies with 0.2% concentration increased significantly when compared control and other concentrations. The effect was found in all combination of crosses. When compared to control, the treatment affected the courtship latency of flies with different concentrations of sertraline. However the difference among different concentrations was insignificant. The treatment appears to have an effect on the progeny also. However, the effect was limited only to the two lower concentrations (i.e.0.2% and 0.4%) and in 0.6% the courtship latency had decreased. Of course the differences in the courtship latency of progeny were also significant. Table 3 and figures 2 shows the effect of duloxetine on courtship latency of D.melanogaster flies. Here the courtship latency was highest in male group with a value of (18.41±0.21). The courtship latency decreased in certain treatments while it had increased in certain other concentrations. For example in both female and male groups, the courtship latency had decreased (10.90±2.18) in 3% concentration while increased in 6% and 12% concentrations (17.19±0.98 and 14.12±0.92 respectively). The differences in the courtship latency of most of the combinations were significant. In contrast to the adult flies, their progeny showed distinct difference in the effect of duloxetine on courtship latency. For example, in both female and male group, the courtship latency had decreased when compared to control while in the male or female groups, the courtship 30

32 latency had increased. The increase in all these combinations was statistically significant. Table 4 and figure 3 shows the effect of doxepin on the courtship latency of Drosophila melanogaster flies with the antidepressant drug doxepin. The scrutiny of the table shows that in both female and male group the courtship latency had increased in all the three concentrations when compared to control. Except 0.5% concentration, the increase was statistically significant. In the female and male groups, the courtship latency was increased at 0.125% concentration and then it was decreased in higher concentrations. Here also the difference in the courtship latency was significant when compared to control. At the highest concentration of 0.5% concentration the courtship latency was lower than that of control. In contrast to this, in the progeny, the treatment lead to an increase in the courtship latency of both female and male group at all concentrations of which 0.25% and 0.5% concentrations the values were significant. The courtship latency of female group had decreased compared to control while male groups showed a decrease in the courtship latency. The effect of the treatment on courtship latency was significant in most of the treatments. Table 5 and figure 4 shows the effect of nortryptyline on courtship latency of D.melanogaster flies with three different concentrations. The treatment has lead to an increase of courtship latency in male and both male and female groups. In the female group, the courtship latency was decreased at 0.25% and 0.5% concentrations when compared to control (2.50± 0.71 and 2.05 ± 0.29). The courtship latency was increased only in 1.0% concentration 31

33 which was the highest concentration used. The increase or the decrease in the courtship latency was statistically significant in most of the cases. In the progeny also the courtship latency was increased in all the three concentrations of both female and male groups, while in the male and female groups the courtship latency had decreased. Here also the differences in the courtship latency between control and was statistically significant. The mean mating latency of the D.melanogaster flies with different concentrations of sertraline is shown in table 6 and figure 5. The table shows that the treatment of sertraline has lead to a decrease in the mating latency in most of the treatments. For example in the female groups the mating latency of control was (16.86 ± 1.32) while in 0.2% and 0.4% concentrations mating latency was (7.93 ± 0.95) and (6.72 ± 1.35) respectively. Only in 0.6% concentration, the mating latency had increased. Similar result was observed in the male and both male and female group also mating latency had decreased when compared to control. The difference in the mating latency in most of these treatments was also statistically significant. Similar results were found in the progenies of these groups showing that the sertraline treatment decreases the mating latency of the courting flies. The effect of treatment of duloxetine on the mean mating latency of the D.melanogaster flies is shown in table 7 and figure 6. The careful observation of the table shows that like sertraline treatment, the treatment of duloxetine also leads to a decrease in the mating latency in most of the treatments. For example in the female groups the mating latency of control was (16.6 ± 1.32) while in 3% it was (12.93 ± 0.95) minutes. Although there was a slight increase in the mating latency at 32

34 6% concentration when compared to control, the increase was not significant. In the male and both male and female groups the mating latency was reduced in all concentrations when compared to control. Interestingly in the progeny of the groups the mating latency had increased in all the treatments and in all the concentrations. More over in most of the cases the increase in the mating latency was significant when compared to control and also when different treatments are compared. Here it is evident that the treatment of duloxetine although has no immediate effect, the progeny of the groups are affected by the treatments. The effect of doxepin treatment on the mean mating latency of the D.melanogaster flies is depicted in table 8 and figure 7. This table shows that the effect of doxepin on the mating latency is different from those of sertraline or duloxetine. In the female group, the mating latency was significantly decreased in 0.125% and 0.5% concentrations while there was no change in the mating latency in 0.25% concentration. The mating latency of flies in this group at 0.25% concentration was (13.00 ± 1.66) which when compared to control was insignificant. In contrast to this, the mating latency in the male and both male and female groups had increased due to the treatment. However, among these two groups, the mating latency of males with different concentrations showed insignificant differences when compared to control. On the other hand the difference in the mating latency between control and various concentrations of doxepin was significant. In the progeny of both groups also the mating latency was increased significantly while in other groups the progeny flies showed inconsistent differences compared to control. 33

35 Table 9 and figure 8 shows the effect of nortryptyline on mean mating latency of control and the group of D.melanogaster. It is observed that the nortryptyline treatment affects the mating latency of all groups. In the female group, the mating latency of control was (3.73 ± 0.61) whereas in 0.25% concentration mating latency was (15.28 ± 1.84). The lowest mating latency in the female group was (4.05 ± 0.48) which was the lowest mating latency of all groups. Furthermore, this value was higher than that of control. Except for the mating latency between 0.5% and 1.0% in the male group and 0.25% and 1.0% concentrations of both male and female groups, all other combinations showed significant difference in the mating latency between the control and groups. In some combinations of the progeny of nortryptyline groups the mating latency had decreased while in others it had increased. The mating latency of flies with 0.25% and 1.0% in the female groups, 0.25% in the male group and 1.0% in the both male and female groups, the mating latency had decreased when compared to control while in others the mating latency had increased. Whether it is decrease or increase the difference between the control and was significant in most of the cases. Table 10 and figure 9 shows that the sertraline treatment to the D.melanogaster flies decreases the copulation duration. The copulation duration of un flies in the female group was (24.18 ± 0.18), while in the groups it was (22.80 ± 1.56); (22.01 ± 1.75); (19.90 ± 1.22) respectively in 0.2%, 0.4% and 0.6% concentrations respectively. Similarly in the male group, the copulation duration of control flies was (24.16 ± 0.21) and the copulation duration of the three concentrations were (20.56 ± 0.14), (21.41 ± 0.90) and (16.62 ± 0.69) respectively. 34

36 In the both sex groups also the copulation duration had decreased when compared to control. However, the decrease was not statistically significant in male groups and in some combinations of female and both sex groups. When the copulation duration of the progeny of these flies were analyzed, it showed that in some combinations the treatment decreased the copulation duration while in others it increased the copulation duration. In all the three groups, the difference between the control and was significant. However, the differences among different concentrations are compared, the values were insignificant. In table 11 and figure 10 the effect of duloxetine on copulation duration on the D.melanogaster flies is shown. The copulation duration of the flies was decreased in both female and male groups when compared to control. The decrease was significant particularly when the copulation duration of groups was compared with control and between different treatments the increase was nonsignificant. In contrast to this, in both female and male group the copulation duration had decreased compared to control. The copulation duration was (18.75± 0.68) minutes in control while it was (13.90 ± 0.30), (12.55 ± 1.15), and (15.55 ± 1.01) minutes in 3%, 6% and 12% concentrations respectively. When compared to control here also the decrease was significant. In the progeny of these groups, the copulation duration had increased in 12% of female group (18.40 ± 1.02) and both female and male (both ) group while in all other concentrations, the copulation duration had decreased. Here also the differences in the copulation duration of control and were statistically significant while between different treatments the differences were insignificant. 35

37 Table 12 and figure 11 shows the effect of doxepin on the copulation duration of D.melanogaster flies with different concentration of the antidepressant drug. The scrutiny of the table shows that only 0.25% concentration of doxepin increases the copulation duration of the flies in the female group (24.70 ± 1.67). The increase when compared to control was statistically significant. The copulation duration was decreased in most of the concentrations of male as well as both female and male groups. In the progeny, the copulation duration had increased in 0.25% of female, and in all the concentrations of male groups. In both female and male group the copulation duration had decreased when compared to control. The effect of different concentrations of nortryptyline on copulation duration of D.melanogaster is shown in table 13 and figure 12. Compared to control, the copulation duration of the flies had increased in some treatments and decreased in others. For example, in the female group, copulation duration was decreased in 0.25% while increased in 0.5% and 1.0% concentrations. Moreover, except between 0.5% and 1.0% concentration the increase was not significant. Similar result was obtained in the male groups. Here 1% concentration showed significant difference when compared with other concentrations. In both female and male group, the copulation duration had decreased in 0.25 and 1.0% concentration while it was increased in 0.5% concentration. The progeny of these flies also showed no distinct trend with regard to copulation duration. In some concentrations or treatments, the duration had increased while in others it had decreased; of course the differences were significant when compared to control or with other concentrations. 36

38 Discussion: Sexuality is one of the important events in the life time of sexually reproducing organisms. During this process the two sexes alternately produce stimuli to which each of them responds. Through this well knit stimulus-response mechanism they produce the offspring which allows the perpetuation of the species. This stimulus-response mechanism is affected by various factors both intrinsic and extrinsic. The intrinsic factors include the physiological condition of both male and female, including hormones and pheromones. The extrinsic factors include both normal and artificial environments. The sexual behavior could be affected even by the extreme conditions such as treatments of drugs or antibiotics. In the present studies the author has noticed the reduction in courtship latency of D.melanogaster flies when they are fed with the antidepressant drug sertraline (table 2). Sertraline belongs to (SSRI). Treatment of other antidepressants namely, duloxetine (SNRI), doxepin (TCA) and nortryptyline (MAOI) had affected the courtship latency but the results were inconsistent (tables 3-5). In some concentration the courtship latency was increased while in others it was decreased. Of course the differences between the control and the were statistically significant. It is evident that the antidepressants affect the courtship latency. The results of the author also show that different classes of antidepressants have different type of effects on the sexual behavior. Courtship latency is one of the parameters which indicate the vigor of male D.melanogaster (Eastwood and Burnett 1977). It represents the time between introduction of male and female flies in to the observation chamber and initiation of courtship (Markow and Kerr 1978, 1985, Markow and Ankey 1988; Hegde and 37

39 Krishna 1997). A male with high vigor reacts quickly in the presence of female while the one with less vigor reacts slowly (Markow and Kerr 1978). The present studies of the author thus show that the antidepressant treatment affects the courtship latency and in particular, sertraline increases the vigor of males. Selective serotonin reuptake inhibitors (SSRIs) are known to induce delayed orgasm and ejaculation, while their effect on other aspects of sexual function, such as sexual motivation, arousal, and erectile function are unclear. In humans Sukoff et al (2008) showed that antidepressive long-term treatment (citalopram and fluoxetine) delays ejaculation but did not affect sexual desire. In addition, several evidences observed that, in male rats, acute administration of fluoxetine results in an inhibition of sexual behavior evidenced by prolonged ejaculation latency and/or by increased number of mounts and/or intromissions exhibited prior to ejaculation (Baum and Starr 1980; Yells et al 1992, 1994, 1995). Taylor et al (1983) showed that the effects of administration of fluoxetine did not modify the propensity of the male rat however; the copulatory pattern was altered in those rats, which exhibited longer latencies of intromission. Serotonin reuptake inhibitors, despite marked differences in chemical structure, induce similar sexual side effects; it is likely that these effects are, indeed, attributable to inhibition of the serotonin transporter and to a subsequent increase in the synaptic concentrations of serotonin (Matuszczyk et al 1998). The author's observation further confirms that the sertraline treatment can cause secondary side effects. Mating latency is time introduction of female and males in to mating chamber until initiation of copulation (Lucic and Kekic 2009). In the present study of the author has noticed significant decrease in the mating latency of flies with sertraline (table 6). Although 0.6% concentration has lead to a slight increase in the 38

This initial discovery led to the creation of two classes of first generation antidepressants:

This initial discovery led to the creation of two classes of first generation antidepressants: Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out

More information

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD

Diagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty

More information

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive

More information

COMPARATIVE BEHAVIOURAL ANALYSIS OF MATING BETWEEN YELLOW AND WILD TYPE DROSOPHILA OF MELANOGASTER SPECIES GROUP

COMPARATIVE BEHAVIOURAL ANALYSIS OF MATING BETWEEN YELLOW AND WILD TYPE DROSOPHILA OF MELANOGASTER SPECIES GROUP Journal of Scientific Research Vol. 58, 2014 : 45-50 Banaras Hindu University, Varanasi ISSN : 0447-9483 COMPARATIVE BEHAVIOURAL ANALYSIS OF MATING BETWEEN YELLOW AND WILD TYPE DROSOPHILA OF MELANOGASTER

More information

Anti-Depressant Medications

Anti-Depressant Medications Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change

More information

Nortriptyline vs amitriptyline in elderly

Nortriptyline vs amitriptyline in elderly Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are

More information

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected. KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize

More information

Depression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:

Depression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder: Depression major depressive disorder Oldest recognized disorder: melancholia It is a positive and active anguish, a sort of psychical neuralgia wholly unknown to normal life. - William James "I am now

More information

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S.

BRIEF ANTIDEPRESSANT OVERVIEW. Casey Gallimore, Pharm.D., M.S. BRIEF ANTIDEPRESSANT OVERVIEW Casey Gallimore, Pharm.D., M.S. Antidepressant Medication Classes First Generation Tricyclic Antidepressants (TCAs) Monoamine Oxidase Inhibitors (MAOIs) Second Generation

More information

Antidepressants. BMF 83 - Antidepressants

Antidepressants. BMF 83 - Antidepressants Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals in the brain, namely serotonin and

More information

ELIMINATION OF MUTANT TYPES IN SELECTION EXPERIMENT BETWEEN WILD TYPE AND MUTANT EYE COLOUR IN DROSOPHILA ANANASSAE

ELIMINATION OF MUTANT TYPES IN SELECTION EXPERIMENT BETWEEN WILD TYPE AND MUTANT EYE COLOUR IN DROSOPHILA ANANASSAE 73 Journal of Scientific Research Banaras Hindu University, Varanasi Vol. 56, 2012 : 73-79 ISSN : 0447-9483 ELIMINATION OF MUTANT TYPES IN SELECTION EXPERIMENT BETWEEN WILD TYPE AND MUTANT EYE COLOUR IN

More information

Package Insert. Clistin Dry. 24 hours.

Package Insert. Clistin Dry. 24 hours. Package Insert Clistin Dry Product Summary 1. Name of the medicinal product Clistin Dry 2. Qualitative and quantitative composition Dextromethorphan Hbr 10 mg Chlorpheniramine Maleate 2 mg Phenylephrine

More information

Antidepressants. Dr Malek Zihlif

Antidepressants. Dr Malek Zihlif Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric

More information

3. Atypical antidepressants

3. Atypical antidepressants 3. Atypical antidepressants Bupropion, mirtazapine, nefazodone & trazodone. Mixed group that act at several different sites. Bupropion Acts as a weak dopamine & NE reuptake inhibitor. Has short half-life.

More information

ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE

ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Medicinska naklada - Zagreb, Croatia Conference paper ANTIDEPRESSANTS IN USE IN CLINICAL PRACTICE Mark Agius 1 & Hannah Bonnici 2 1 Clare College, University of Cambridge, Cambridge, UK 2 Hospital Pharmacy

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.

More information

Psychobiology Handout

Psychobiology Handout Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are

More information

MANAGEMENT OF VISCERAL PAIN

MANAGEMENT OF VISCERAL PAIN MANAGEMENT OF VISCERAL PAIN William D. Chey, MD, FACG Professor of Medicine University of Michigan 52 year old female with abdominal pain 5 year history of persistent right sided burning/sharp abdominal

More information

WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS

WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS WESTMEAD PRIMARY EXAM GROUP PSYCHOTROPIC MEDICATIONS DOPAMINE HYPOTHESIS Excessive limbic dopamine is hypothesised to cause psychosis Many antipsychotics inhibit dopamine 2 receptors in mesolimbic and

More information

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

Treatment Options for Bipolar Disorder Contents

Treatment Options for Bipolar Disorder Contents Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8

More information

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018

Affective or Mood Disorders. Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Dr. Alia Shatanawi March 12, 2018 Affective or Mood Disorders Reactive Depression. Secondary: Medical Neurological Drugs Major (Endogenous) Depression = Unipolar: Depressed

More information

(levomilnacipran) extended-release capsules

(levomilnacipran) extended-release capsules MEDICATION GUIDE FETZIMA (fet-zee-muh) (levomilnacipran) extended-release capsules Read this Medication Guide before you start taking FETZIMA and each time you get a refill. There may be new information.

More information

Norpramin (desipramine)

Norpramin (desipramine) Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)

More information

Studie 083 (950E-CNS )

Studie 083 (950E-CNS ) Studie 083 (950E-CNS-0005-083) Studienberichtssynopse Clinical Study Report 950E-CNS-0005-083 EFFECTS OF THE USE OF REBOXETINE AS A SUBSTITUTE FOR SELECTIVE SEROTONIN REUPTAKE INHIBITOR ANTIDEPRESSANTS

More information

Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6

Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 Generalized Anxiety Disorder ( DSM -IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control.

More information

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets

PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets PRODUCT INFORMATION CODAPANE XTRA Paracetamol 500 mg and Codeine Phosphate 15 mg Tablets NAME OF THE MEDICINE Active Ingredients: Paracetamol and Codeine Phosphate Paracetamol: Molecular Formula: C 8 H

More information

Common Antidepressant Medications for Adults

Common Antidepressant Medications for Adults (and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10

More information

Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)

Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);

More information

ANTI-DEPRESSANT MEDICATIONS

ANTI-DEPRESSANT MEDICATIONS ANTI-DEPRESSANT MEDICATIONS This information is not intended to be a substitute for medical advice. It s purpose is solely informative. If your client or yourself are taking antidepressants, do not change

More information

Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL

Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg

More information

MEDICATION GUIDE. desvenlafaxine extended-release tablets (des VEN la FAX een)

MEDICATION GUIDE. desvenlafaxine extended-release tablets (des VEN la FAX een) MEDICATION GUIDE desvenlafaxine extended-release tablets (des VEN la FAX een) Read this Medication Guide before you start taking desvenlafaxine extended-release tablets and each time you get a refill.

More information

Pamelor (nortriptyline)

Pamelor (nortriptyline) Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor

More information

Risk Management Plan Rasagiline tablets

Risk Management Plan Rasagiline tablets PART VI: Summary of activities in the risk management plan by product VI.1 VI.1.1 Elements for summary tables in the EPAR Summary table of Safety concerns Summary of safety concerns Important identified

More information

Presentation is Being Recorded

Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE

Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic

More information

TRAPADOL INJECTION FOR I.V./I.M. USE ONLY

TRAPADOL INJECTION FOR I.V./I.M. USE ONLY TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally

More information

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

PRODUCT MONOGRAPH ZONALON CREAM 5% GENERIC NAME DOXEPIN HYDROCHLORIDE CREAM 5% THERAPEUTIC CLASSIFICATION TOPICAL ANTIPRURITIC

PRODUCT MONOGRAPH ZONALON CREAM 5% GENERIC NAME DOXEPIN HYDROCHLORIDE CREAM 5% THERAPEUTIC CLASSIFICATION TOPICAL ANTIPRURITIC PRODUCT MONOGRAPH ZONALON CREAM 5% GENERIC NAME DOXEPIN HYDROCHLORIDE CREAM 5% THERAPEUTIC CLASSIFICATION TOPICAL ANTIPRURITIC Valeant Canada LP. Date of Preparation: Montreal, Quebec March 19, 2013 H4R

More information

Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology

Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology Objective: To discuss basic principles of psychopharmacology in children and adolescents. Pharmacokinetics:

More information

Elavil (amitriptyline)

Elavil (amitriptyline) Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information

More information

Types of behaviors that are elicited in response to simple stimuli

Types of behaviors that are elicited in response to simple stimuli Lecture 19: Animal Behavior I. Background A. Animal behavior reflects and arises from biological properties 1. Exhibited behavior defends on the physiological systems and processes unique to a given organism

More information

Effective Health Care

Effective Health Care Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such

More information

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.

Guilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant. 1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number

More information

DRUGS THAT ACT IN THE CNS

DRUGS THAT ACT IN THE CNS DRUGS THAT ACT IN THE CNS Anxiolytic and Hypnotic Drugs Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 OTHER ANXIOLYTIC AGENTS/ A. Antidepressants Many antidepressants are effective in the treatment

More information

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes. PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine

More information

MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets

MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets FDA-Approved Medication Guide MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants)

More information

Depression in Late Life

Depression in Late Life Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression

More information

Drugs for Emotional and Mood Disorders Chapter 16

Drugs for Emotional and Mood Disorders Chapter 16 Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,

More information

Antidepressant Pharmacology An Overview

Antidepressant Pharmacology An Overview Figure 1. Antidepressant Pharmacology An Overview Source: NEJM 2005;353:1819-34 Figure 2. 1 Figure 3: Antidepressant Pharmacology pictures: Weak inhibition Bupropion NOTE: CYP enzymes noted are those inhibited

More information

SANDOMIGRAN (pizotifen malate)

SANDOMIGRAN (pizotifen malate) SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.

More information

Inheritance of Aldehyde Oxidase in Drosophila melanogaster

Inheritance of Aldehyde Oxidase in Drosophila melanogaster Inheritance of Aldehyde Oxidase in Drosophila melanogaster (adapted from Morgan, J. G. and V. Finnerty. 1991. Inheritance of aldehyde oxidase in Drosophilia melanogaster. Pages 33-47, in Tested studies

More information

PRODUCT INFORMATION. Benadryl* for the Family Nightime Oral Liquid

PRODUCT INFORMATION. Benadryl* for the Family Nightime Oral Liquid Product description PRODUCT INFORMATION Benadryl* for the Family Nightime Oral Liquid Each 5 ml of Benadryl* Nightime oral liquid contains dextromethorphan hydrobromide 10 mg and diphenhydramine hydrochloride

More information

Medications Guide: Public Speaking And Social Anxiety

Medications Guide: Public Speaking And Social Anxiety AnxietyHub.org Dr. Cheryl Mathews Medications Guide: Public Speaking And Social Anxiety Copyright 2016 AnxietyHub Medications Specifically for Public Speaking and Social Anxiety This is not intended to

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Generalised anxiety disorder Generalised anxiety disorder (GAD) is an umbrella term that covers a wide range of anxiety disorders

More information

Quick Guide to Common Antidepressants-Adults

Quick Guide to Common Antidepressants-Adults Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa

More information

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders?

The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders What are functional GI disorders? The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B. Dalton, PA-C Douglas A. Drossman, MD and Kellie Bunn, PA-C What are functional GI

More information

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual

More information

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines

More information

Antidepressants Choosing the Right One

Antidepressants Choosing the Right One Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg

More information

CONSUMER MEDICINE INFORMATION

CONSUMER MEDICINE INFORMATION CONSUMER MEDICINE INFORMATION Arrow - Tramadol Tramadol 50 mg capsules What is in this leaflet This leaflet answers some common questions about ARROW - TRAMADOL. It does not contain all of the available

More information

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*

Management of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors* Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine

More information

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.

Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association

More information

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally

More information

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on

More information

Doctor Discussion Guide

Doctor Discussion Guide Doctor Discussion Guide What should I tell my doctor? Talking to your doctor about depression doesn t have to be as hard as you may think. These simple tips can help you gather information and prepare

More information

Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych

Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych Antidepressants: Prof. Riyadh Al_Azzawi F.R.C.Psych A. Heterocyclic antidepressants: (tricyclic and tetracyclic ), e.g.amitryptaline,imipramine. B. Monoamine oxidase inhibitors(m.a.o.i), e.g.phenelzine.

More information

Experimental evolution under hyperpromiscuity in Drosophila melanogaster

Experimental evolution under hyperpromiscuity in Drosophila melanogaster Perry et al. BMC Evolutionary Biology (2016) 16:131 DOI 10.1186/s12862-016-0699-8 RESEARCH ARTICLE Open Access Experimental evolution under hyperpromiscuity in Drosophila melanogaster Jennifer C. Perry

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Renoux C, Vahey S, Dell Aniello S, Boivin J-F. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. Published

More information

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian. ELANCO ANIMAL HEALTH A Division of Eli Lilly & Co. USA Product Label http://www.vetdepot.com 2500 INNOVATION WAY, GREENFIELD, IN, 46140 Main Switchboard: 317 433 4800 Customer Service: 317 276 1262 Small

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT YOCON-GLENWOOD Tablets 5 mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 tablet contains 5 mg yohimbine hydrochloride. For a full list of excipients, see section 6.1. 3

More information

Austedo. (deutetrabenazine) New Product Slideshow

Austedo. (deutetrabenazine) New Product Slideshow Austedo (deutetrabenazine) New Product Slideshow Introduction Brand name: Austedo Generic name: Deutetrabenazine Pharmacological class: Vesicular monoamine transporter 2 (VMAT2) inhibitor Strength and

More information

Contemporary Psychiatric-Mental Health Nursing. Psychopharmacology. Psychopharmacology - continued. Chapter 7 The Science of Psychopharmacology

Contemporary Psychiatric-Mental Health Nursing. Psychopharmacology. Psychopharmacology - continued. Chapter 7 The Science of Psychopharmacology Contemporary Psychiatric-Mental Health Nursing Chapter 7 The Science of Psychopharmacology Psychopharmacology A primary treatment mode of psychiatric-mental health nursing care Psychopharmacology - continued

More information

Depression in Pregnancy

Depression in Pregnancy TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date

More information

Mental illness A Broad Overview. Dr H Pathmanandam March 2017

Mental illness A Broad Overview. Dr H Pathmanandam March 2017 Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate

More information

1.Suicidal thoughts or actions:

1.Suicidal thoughts or actions: Medication Guide FLUOXETINE (Floa-OX-e-teen) TABLETS, USP Read the Medication Guide that comes with fluoxetine tablets before you start taking it and each time you get a refill. There may be new information.

More information

Tofranil and Tofranil-PM (imipramine)

Tofranil and Tofranil-PM (imipramine) Tofranil and Tofranil-PM (imipramine) Generic name: Imipramine Available strengths: 10 mg, 25 mg, 50 mg tablets; 75 mg, 100 mg, 125 mg, 150 mg capsules (Tofranil-PM) Available in generic: Yes Drug class:

More information

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES

PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14

More information

PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS

PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS PHARMACODYNAMICS OF ANTIDEPRESSANTS MOOD STABILIZING AGENTS ANXIOLYTICS SEDATIVE-HYPNOTICS Yogesh Dwivedi, Ph.D. Assistant Professor of Psychiatry and Pharmacology Psychiatric Institute Department of Psychiatry

More information

Pharmacists in Medication Adherence in Psychiatric Patients

Pharmacists in Medication Adherence in Psychiatric Patients Pharmacists in Medication Adherence in Psychiatric Patients Mamta Parikh, PharmD, BCPS, BCPP Assistant Professor, Clinical and Administrative Sciences Notre Dame of Maryland University School of Pharmacy

More information

Depression Pharmacology. PHPP 517 (IT-III) Fall 2011

Depression Pharmacology. PHPP 517 (IT-III) Fall 2011 Depression Pharmacology PHPP 517 (IT-III) Fall 2011 Depression Symptoms of Depression Emotional symptoms Physical symptoms Cognitive symptoms Psychomotor symptoms Depression Pharmacology Loss of brain

More information

Mood Disorders.

Mood Disorders. Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Medication Guide Fluoxetine Tablets, USP

Medication Guide Fluoxetine Tablets, USP Medication Guide Fluoxetine Tablets, USP Read the Medication Guide that comes with fluoxetine before you start taking it and each time you get a refill. There may be new information. This Medication Guide

More information

Rare male mating advantage in Drosophila melanogaster.

Rare male mating advantage in Drosophila melanogaster. Dros. Inf. Serv. 92 (2009) Teaching Notes 155 Rare male mating advantage in Drosophila melanogaster. Benson, Jennifer L., Adam M. Boulton, Caroline W. Coates, Amanda C. Lyons, Sarah J. Rossiter, and R.C.

More information

Partners in Care Quick Reference Cards

Partners in Care Quick Reference Cards Partners in Care Quick Reference Cards Supported by the Agency for Healthcare Research and Quality MR-1198/8-AHRQ R This project was funded by the Agency for Healthcare Research and Quality (AHRQ), formerly

More information

Depression & Anxiety in Adolescents

Depression & Anxiety in Adolescents Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with

More information

Anxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Anxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming

More information

Medication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets

Medication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets Medication Guide SARAFEM (SAIR-a-fem) (fluoxetine hydrochloride) Tablets Read the Medication Guide that comes with SARAFEM before you start taking it and each time you get a refill. There may be new information.

More information

Consumer Medicine Information

Consumer Medicine Information Consumer Medicine Information TRAMAL SR Tramadol hydrochloride Sustained Release Tablets What is in this leaflet? This leaflet answers some common questions about Tramal SR. It does not contain all the

More information

TREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD

TREATMENT OF DEPRESSION IN LATE LIFE. Robert Kohn, MD TREATMENT OF DEPRESSION IN LATE LIFE Robert Kohn, MD WHY TREAT ELDERLY PERSONS Major depression is not a normal part of aging The rates are lower than younger cohorts The prevalence rates are still high

More information

PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other.

PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Product description PANADOL COLD & FLU RELIEF ORIGINAL FORMULA is a white, capsule-shaped tablet with flat edges, one face marked with C&F, PANADOL on the other. Ingredients Active Ingredients: Paracetamol

More information

Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination)

Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination) Symbyax (Zyprexa [olanzapine] and Prozac [fluoxetine] combination) Generic name: Olanzapine and fluoxetine combination Available strengths: 6 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, 12 mg/50 mg (Zyprexa/Prozac)

More information

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry

Antidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free

More information

Thiophanate-methyl -MATERIAL SAFETY DATA SHEET

Thiophanate-methyl -MATERIAL SAFETY DATA SHEET Thiophanate-methyl -MATERIAL SAFETY DATA SHEET 1. Chemical Product Identification Product Name: Thiophanate-methyl Molecular Formula: C 12 H 14 N 4 O 4 S 2 Molecular Weight: 342.4 Structural Formula: Chemical

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET 1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full

More information

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including: Medication Guide VENLAFAXINE XR (venlafaxine hydrochloride) (Extended-Release Capsules) Read the Medication Guide that comes with venlafaxine hydrochloride extended-release before you start taking it and

More information

Medication Guide Escitalopram Tablets (ES-sye-TAL-oh-pram)

Medication Guide Escitalopram Tablets (ES-sye-TAL-oh-pram) Medication Guide Escitalopram Tablets (ES-sye-TAL-oh-pram) Read the Medication Guide that comes with escitalopram tablets before you start taking it and each time you get a refill. There may be new information.

More information